65,437 trials
Diabetes Mellitus
Primary: Glycosylated Haemoglobin A1c at Start — 6.64; 6.76 Percentage
Postoperative Nausea and Vomiting
Primary: Experienced Post-operative Nausea or Vomiting — 25; 29; 20; 30 participants
Renal Transplant
Primary: Mycophenolic Acid (MPA) Maintenance Treatment — 47.06; 16.39 Percentage of Patients
Rheumatoid Arthritis
Primary: Frequency of Adverse Events — 38; 1; 1; 24 participants
Postmenopausal Osteoporosis
Primary: Percentage Change From Baseline Serum Type-1 Collagen C-telopeptide (CTX) 75 mg & 100 mg DRFB Tablet Compared With 150 mg IRBB Tablet, Month 4, ITT Population — -41.235…
Glaucoma
Primary: Mean Change in the Peak Intraocular Pressure (IOP) Measured Two Hours After Study Drug Administration at Week 12 Compared to Baseline IOP. — -3.73 mmHg — p=<0.0001
Alzheimer's Disease
Primary: Percentage of Patients Who Had a Gastrointestinal Adverse Event (AE) at Any Time During the Study — 4.65; 4.26; 6.12 Percentage of participants
Acute Myelogenous Leukemia · Acute Myeloid Leukemia
Primary: Percentage of Participants Achieving Overall Remission (OR) After No More Than Two Cycles (Approximately Month 2) — 45.5; 37.5; 8.0; 3.6 percentage of participants
Dry Eye
Primary: Ocular Comfort Level From Baseline to End of Study — 0.68; 0.84; 0.24; 0.31 Units on a scale
Hepatitis C, Chronic
Primary: The Percentage of Participants Who Achieved a Sustained Virologic Response (SVR) — 56.41; 67.07 Percentage of participants — p=0.1651
Melanoma
Primary: Number of Participants With Disease Recurrence — 52 participants
Myopia · Astigmatism
Primary: Overall Comfort — 7.6; 7.6 Units on a Scale
Human Papillomavirus (HPV) Infection
Primary: Number of Seroconverted Subjects for Anti-human Papillomavirus (HPV)-16 and 18 Antibodies — 130; 4; 190; 5 Participants
Hypertension
Primary: Change in Mean Sitting Diastolic Blood Pressure (msDBP) From Baseline to End of Study — -10.99; -8.95; -7.23 mm Hg
Lung Cancer
Primary: Patient Response — 2; 1; 2; 27 participants